THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 125 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $120,725 | -17.9% | 13,989 | -1.5% | 0.00% | 0.0% |
| Q2 2023 | $147,042 | -7.4% | 14,207 | -3.0% | 0.00% | 0.0% |
| Q1 2023 | $158,844 | -12.5% | 14,640 | -9.5% | 0.00% | -50.0% |
| Q4 2022 | $181,472 | +15.6% | 16,174 | +4.3% | 0.00% | 0.0% |
| Q3 2022 | $157,000 | +15.4% | 15,513 | +3.6% | 0.00% | +100.0% |
| Q2 2022 | $136,000 | -4.9% | 14,979 | +0.3% | 0.00% | 0.0% |
| Q1 2022 | $143,000 | -12.8% | 14,941 | +0.7% | 0.00% | 0.0% |
| Q4 2021 | $164,000 | +50.5% | 14,831 | +0.9% | 0.00% | 0.0% |
| Q3 2021 | $109,000 | -38.4% | 14,705 | +20.8% | 0.00% | 0.0% |
| Q2 2021 | $177,000 | -33.5% | 12,174 | -6.6% | 0.00% | -50.0% |
| Q1 2021 | $266,000 | +16.2% | 13,038 | +1.1% | 0.00% | 0.0% |
| Q4 2020 | $229,000 | +16.2% | 12,894 | -3.2% | 0.00% | 0.0% |
| Q3 2020 | $197,000 | -4.8% | 13,325 | +34.9% | 0.00% | -33.3% |
| Q2 2020 | $207,000 | -10.4% | 9,878 | -1.2% | 0.00% | -25.0% |
| Q1 2020 | $231,000 | – | 9,994 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Woodford Investment Management Ltd | 11,213,879 | $254,331,000 | 30.84% |
| Cormorant Asset Management, LP | 1,300,000 | $29,484,000 | 2.18% |
| Baupost Group | 9,309,168 | $211,132,000 | 1.85% |
| SENZAR ASSET MANAGEMENT, LLC | 27,397 | $621,000 | 1.79% |
| ARMISTICE CAPITAL, LLC | 1,180,000 | $26,762,000 | 1.75% |
| Old West Investment Management, LLC | 111,101 | $2,519,000 | 1.27% |
| Chescapmanager LLC | 403,321 | $9,147,000 | 1.06% |
| Virtus ETF Advisers LLC | 30,055 | $682,000 | 0.60% |
| Rock Springs Capital Management LP | 652,600 | $14,801,000 | 0.57% |
| Foundation Asset Management, LP | 27,154 | $616,000 | 0.53% |